Research presented at the Alzheimer’s Association International Conference 2025 highlights substantial structural brain changes and cognitive deficits in breast cancer patients within a year of undergoing anthracycline-taxane chemotherapy. The study, encompassing 270 participants, utilized advanced neuroimaging techniques to reveal reduced grey matter volumes and surface areas in critical brain regions associated with memory and executive function. These findings suggest that chemotherapy may cause neuroinflammation and vascular toxicity, contributing to long-lasting cognitive impairment in approximately 33% of breast cancer survivors, often referred to as 'Chemobrain'.

Source: AAIC 2025